Results 61 to 70 of about 67,411 (205)

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

Journal of Clinical Oncology, 2019
PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in ...
F. Ma, Q. Ouyang, Wei Li, Zefei Jiang, Z. Tong, Yunjiang Liu, Huiping Li, Shiying Yu, Jifeng Feng, Shusen Wang, Xichun Hu, J. Zou, Xiaoyu Zhu, Bing-he Xu   +13 more
semanticscholar   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study

BMC Cancer, 2022
Background Distant metastasis has been the main failure pattern for locoregionally advanced rectal cancer (LARC) patients, and intensified neoadjuvant chemotherapy has become a popular research topic.
Anchuan Li, Tingxuan Huang, Rong Zheng, Pan Chi, Zhihua Li, Xiaozhong Wang, Benhua Xu   +6 more
doaj   +1 more source

Predicting the Efficacy of Adjuvant Chemotherapy Using Immuno‐Nutritional and Inflammatory Markers in Elderly Patients With Stage III Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
This study aimed to determine whether immuno‐nutritional and inflammatory markers could serve as predictors of the outcomes of postoperative adjuvant chemotherapy for stage III colorectal cancer in elderly patients. Postoperative lymphocyte‐to‐monocyte ratio and postoperative C‐reactive protein‐to‐albumin ratio accurately predicted the efficacy of ...
Tomoya Tago, Yasuyuki Takamizawa, Takeharu Kato, Hiroshi Nagata, Konosuke Moritani, Shunsuke Tsukamoto, Yukihide Kanemitsu   +6 more
wiley   +1 more source

Drug-Induced Hand-Foot Syndrome in Cancer Patients Receiving Capecitabine in A Tertiary Care Hospital

Pakistan Armed Forces Medical Journal, 2023
Objective: To determine the frequency of hand-foot syndrome and associated factors among patients receiving Capecitabine for the management of cancer in a tertiary care setting. Study Design: Cross-sectional study.
Ibtisam Idrees, Riaz Ahmad, Muhammad Umair, Anum Zargham, Mir Jalal-ud- Din, Tahir Manoor Lone   +5 more
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

Journal of Clinical Oncology, 2020
PURPOSE Standard adjuvant chemotherapy for triple-negative breast cancer (TNBC) includes a taxane and an anthracycline. Concomitant capecitabine may be beneficial, but robust data to support this are lacking.
Junjie Li, Keda Yu, D. Pang, Changqing Wang, Jun Jiang, Suisheng Yang, Yunjiang Liu, P. Fu, Y. Sheng, Guojun Zhang, Yali Cao, Q. He, S. Cui, Xijing Wang, G. Ren, Xinzheng Li, Shi-ping Yu, Peng-xi Liu, X. Qu, Jin-hai Tang, O. Wang, Z. Fan, G. Jiang, Jin Zhang, Jiandong Wang, Hongwei Zhang, Shui Wang, Jian-guo Zhang, Feng Jin, N. Rao, B. Ma, P. He, Bing-he Xu, Z. Zhuang, Jianfeng Wang, Q. Sun, Xiaofeng Guo, M. Mo, Z. Shao   +38 more
semanticscholar   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

Adherence to Capecitabine Among Patients With Gastrointestinal Cancer: A Prospective Cohort Study

Acta Medica Iranica, 2023
Adherence to capecitabine, an effective oral chemotherapy agent, is essential in achieving treatment response in cancer. In this study, we aimed to investigate factors associated with non-adherence to capecitabine in a sample of patients with ...
Ahmad Khajeh-Mehrizi, Seyed Amir Hossein Emami, Seyed Reza Safaee Nodehi, Zahra Jahangard-Rafsanjani, Kamran Roudini, Mohammad Reza Dabiri, Seyed Amir Mahdi Emami   +6 more
doaj   +1 more source